MII Implementierungsleitfaden Kerndatensatz-Modul Molekulargenetischer Befundbericht
2027.0.0-ballot.1 -
Germany
MII Implementierungsleitfaden Kerndatensatz-Modul Molekulargenetischer Befundbericht
2027.0.0-ballot.1 -
Germany
This page is part of the MII IG Kerndatensatz-Modul Molekulargenetischer Befundbericht (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions
{
"resourceType" : "Observation",
"id" : "mii-exa-molgen-therapeutische-implikation-fgfr2-fusion",
"meta" : {
"profile" : [
🔗 "https://www.medizininformatik-initiative.de/fhir/ext/modul-molgen/StructureDefinition/therapeutische-implikation|2027.0.0-ballot.1"🔗 ,
"http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/therapeutic-implication|3.0.0"
]
},
"language" : "de",
"text" : {
"status" : "generated",
"div" : "<div xml:lang=\"de\" lang=\"de\"><hr/><p><b>German</b></p><hr/><p class=\"res-header-id\"><b>Generated Narrative: Observation mii-exa-molgen-therapeutische-implikation-fgfr2-fusion</b></p><a name=\"de-mii-exa-molgen-therapeutische-implikation-fgfr2-fusion\"> </a><a name=\"de-hcmii-exa-molgen-therapeutische-implikation-fgfr2-fusion\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profiles: <a href=\"StructureDefinition-mii-pr-molgen-therapeutische-implikation.html\">MII PR MolGen Therapeutische Implikation</a> version: 2027.0.0-ballot.1, <a href=\"http://hl7.org/fhir/uv/genomics-reporting/STU3/StructureDefinition-therapeutic-implication.html\">Therapeutic Implication</a> version: 3.0.0</p></div><p><b>status</b>: Final</p><p><b>category</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/observation-category laboratory}\">Laboratory</span>, <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/v2-0074 GE}\">Genetik</span></p><p><b>code</b>: <span title=\"Codes:{http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs therapeutic-implication}\">Therapeutic Implication</span></p><p><b>subject</b>: <a href=\"Patient-mii-exa-molgen-patient-fgfr2-fusion.html\">Anonymous Patient Female, DoB: 1964-05 ( pseudonymized\u00a0(use:\u00a0usual,\u00a0))</a></p><p><b>effective</b>: 2022-11-30</p><p><b>performer</b>: <a href=\"Practitioner-mii-exa-molgen-practitioner-lab.html\">Practitioner Dr. Daniel Schmidt(official)</a></p><p><b>derivedFrom</b>: <a href=\"Observation-mii-exa-molgen-variante-fgfr2-fusion.html\">Observation Genetic variant assessment</a></p><blockquote><p><b>component</b></p><p><b>code</b>: <span title=\"Codes:{http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs conclusion-string}\">Conclusion Text</span></p><p><b>value</b>: Hochselektiver FGFR2-Inhibitor RLY-4008 bei Patienten mit Cholangiokarzinomen und anderen soliden Tumoren, mit oder ohne FGFR- gerichtete Vortherapie.</p></blockquote><blockquote><p><b>component</b></p><p><b>code</b>: <span title=\"Codes:{http://loinc.org 51963-7}\">Medication assessed [ID]</span></p><p><b>value</b>: <span title=\"Codes:{http://www.whocc.no/atc L01EN}, {http://snomed.info/sct 1162485005}\">Fibroblasten-Wachstumsfaktor-Rezeptor (FGFR)-Tyrosinkinase-Inhibitoren</span></p></blockquote><blockquote><p><b>component</b></p><p><b>code</b>: <span title=\"Codes:{http://loinc.org 93044-6}\">Level of evidence</span></p><p><b>value</b>: <span title=\"Codes:\">m1c</span></p></blockquote><blockquote><p><b>component</b></p><p><b>code</b>: <span title=\"Codes:{http://loinc.org 81259-4}\">Associated phenotype</span></p><p><b>value</b>: <span title=\"Codes:{http://snomed.info/sct 109842005}, {http://fhir.de/CodeSystem/bfarm/icd-10-gm C22.1}\">Intrahepatic bile duct carcinoma (disorder)</span></p></blockquote></div>"
},
"status" : "final",
"category" : [
{
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/observation-category",
"code" : "laboratory",
"display" : "Laboratory"
}
]
},
{
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0074",
"code" : "GE"
}
]
}
],
"code" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs",
"code" : "therapeutic-implication",
"display" : "Therapeutic Implication"
}
]
},
"subject" : {
🔗 "reference" : "Patient/mii-exa-molgen-patient-fgfr2-fusion"
},
"effectiveDateTime" : "2022-11-30",
"performer" : [
{
🔗 "reference" : "Practitioner/mii-exa-molgen-practitioner-lab"
}
],
"derivedFrom" : [
{
🔗 "reference" : "Observation/mii-exa-molgen-variante-fgfr2-fusion"
}
],
"component" : [
{
"code" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs",
"code" : "conclusion-string"
}
]
},
"valueString" : "Hochselektiver FGFR2-Inhibitor RLY-4008 bei Patienten mit Cholangiokarzinomen und anderen soliden Tumoren, mit oder ohne FGFR- gerichtete Vortherapie."
},
{
"code" : {
"coding" : [
{
"system" : "http://loinc.org",
"code" : "51963-7",
"display" : "Medication assessed [ID]"
}
]
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://www.whocc.no/atc",
"code" : "L01EN",
"display" : "Fibroblasten-Wachstumsfaktor-Rezeptor (FGFR)-Tyrosinkinase-Inhibitoren"
},
{
"system" : "http://snomed.info/sct",
"code" : "1162485005",
"display" : "Substance with fibroblast growth factor receptor inhibitor mechanism of action (substance)"
}
]
}
},
{
"code" : {
"coding" : [
{
"system" : "http://loinc.org",
"code" : "93044-6"
}
]
},
"valueCodeableConcept" : {
"text" : "m1c"
}
},
{
"code" : {
"coding" : [
{
"system" : "http://loinc.org",
"code" : "81259-4"
}
]
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "109842005",
"display" : "Intrahepatic bile duct carcinoma (disorder)"
},
{
"system" : "http://fhir.de/CodeSystem/bfarm/icd-10-gm",
"version" : "2024",
"code" : "C22.1",
"display" : "Intrahepatisches Gallengangskarzinom"
}
]
}
}
]
}